MOUNTAIN VIEW, Calif., May 22, 2014 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that data from a one-year, multi-center study demonstrates the safety and durability of its proprietary MicroPulse technology as a treatment for glaucoma. The educational symposium was led by Drs. Ike Ahmed, David Gossage, and Elias Reichel and was attended by more than 300 ophthalmologists during the American Society of Cataract and Refractive Surgeons (ASCRS) conference in April.
"The one-year results showed a sustained intra-ocular pressure (IOP) decrease of 20-25%," reported Dr. Ahmed, a glaucoma specialist, based on data he calculated along with Drs. Nathan Radcliffe, Steven Vold and David Gossage. "This multi-center study provides evidence that pressure lowering with MicroPulse Laser Trabeculoplasty is both safe and durable. This therapy can be considered a first-line treatment for glaucoma patients, as well as patients who haven't seen significant effects from medications."
Will Moore, CEO of IRIDEX commented, "Prior studies have substantiated the safety, efficacy, and durability of MicroPulse for treating various retinal diseases caused by diabetes." Moore continued, "With the addition of this data for glaucoma, we believe the versatility of our MicroPulse laser systems are ideally suited to the broader global market of comprehensive ophthalmologists."
The complete video recording of the symposium will be published on the IRIDEX website (www.iridex.com) once available.
About MicroPulse Technology
MicroPulse is a Fovea-friendly tissue-sparing laser delivery therapy that works by electronically "chopping" the laser emission into trains of microsecond pulses. This allows the physician to blanket the affected tissue with laser energy while allowing the tissue to cool between pulses, offering the potential for ocular treatment with less collateral effects than conventional laser treatments.
About IRIDEX IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through both direct and independent sales forces and internationally through a combination of a direct sales force and a network of approximately 70 independent distributors into over 100 countries. For further information, visit the Company's website at http://www.iridex.com.
Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, relating to the size and growth of markets in which the Company operates, US and international buying patterns, the success of the Company's marketing and sales efforts and operational execution, the effectiveness and adoption of, demand for, and health risks associated with MicroPulse laser therapy and the Company's other products, anticipated new product releases and the effect of the foregoing on the Company's business, business prospects, financial results and competitive position. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended December 28, 2013, which was filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.
SOURCE IRIDEX Corporation